The FDA Just Voted on 7 Peptides. Here's What Changed (And What Didn't)

On July 23-24, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) made a major decision: whether seven of the most talked about peptides should move onto the approved list for compounding in the U.S. 

‍

The peptides under review were: BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and DSIP.

‍

Six passed. One didn’t.

‍

That sounds decisive, but the reality is more nuanced than that.

‍

What the committee voted

‍

Across two days, the committee reviewed each peptide individually:

• BPC-157, KPV, and TB-500 each passed 8-6 (with one abstention)
• MOTS-c passed 7-5
• Semax passed 8-5
• Epitalon passed 7-5
• DSIP was rejected 6-7

‍

In total, six of seven peptides got a positive recommendation for potential compounding.

‍

Why is this such a big deal?

Because the FDA’s own career scientists had recommended against all seven, citing limited safety data and gaps in chemical characterization. 

‍

As you can see, the committee ultimately voted against that guidance, which is something that does not happen often. That’s why this decision is getting so much attention beyond just the niche peptide circles. 

‍

What this does not mean (yet)

‍

The PCAC is an advisory body. Its vote is a recommendation, not a rule change. For any of these peptides to become Category 1, the FDA has to go through formal rulemaking. That includes:

1. Publishing a proposed rule
2. Opening a public comment period
3. Issuing a final rule

‍

That process usually takes several months.

‍

Why the vote is more complicated than it looks

‍

This wasn’t exactly a unanimous or uncontested decision, and it’s worth understanding both sides of it.

‍

Critics raised real concerns. A number of committee members were newly appointed just weeks before the meeting. Some members have disclosed ties to clinics that offer peptide therapies. And major organizations (including the American Pharmacies Association and the Partnership for Safe Medicines) formally opposed adding any of the seven peptides, saying there are safety concerns and limited clinical data.

‍

Supporters make an equally specific case about a major risk: the existing peptide gray market. This is where product purity, dosing accuracy, and contamination are, honestly, unverifiable. 

‍

One committee member described a patient who brought in a “research-grade” peptide that tested positive for MDMA and ecstasy contamination — the exact kind of risk a licensed and monitored pathway is designed to reduce. 

‍

This contamination example is, unfortunately, not an isolated issue. This kind of thing happens often in the unregulated gray market these peptides currently exist in.

‍

Supporters argue that a regulated compounding pathway is safer than the current alternative. And it's a strong argument.

‍

What this means for wellness businesses 

‍

If the FDA follows the committee’s recommendation to move 6 of the 7 proposed peptides to Category 1, there could be a more regulated pathway to offer BPC-157, TB-500, and the others.

‍

It’s also worth noting that this vote runs in the opposite direction of what’s happening with GLP-1 compounding, where the FDA has moved to restrict access rather than expand it.

‍

All of this is evidence that the peptide regulatory landscape isn’t moving in a single direction right now. Instead, it’s evolving case by case.

‍

FAQs

‍

Did the FDA approve these peptides as drugs?

No. This approval process is about whether compounding pharmacies can legally prepare these substances for patients with a prescription. That’s a different and much lower bar than full FDA drug approval.  Currently, these peptides are not FDA-approved drugs or medications.

‍

What happens next?

The FDA will review the committee’s recommendation and decide whether to begin formal rulemaking. If it doesn't, you can expect a timeline of at least 6-12 months before any change takes effect.

‍

Where this leaves you

‍

This is one of the most significant moments for peptides in years, but it is still early.

The demand for these peptides has already outgrown the current regulatory framework. People are seeking access whether or not a safe pathway exists. This is the risk the gray market creates for consumers who are eager. 

‍

So, when that demand gets met through unverified, unregulated sources instead of licensed ones, it stops being just a compliance issue and becomes a public safety issue. 

‍

That’s why we support moving peptides with reasonable clinical evidence behind them onto the Category 1 pathway. It gives people a safer, clinician-supervised way to access them. And, as the regulations evolve, those who can provide safe sourcing with clinician oversight will be able to best support their clients. 

‍

For practices and wellness brands, the smartest move right now is to stay informed.

‍

Many wellness businesses are already offering Category 1 peptides through platforms like Altro.

‍

We help coaches, medspas, and wellness centers offer peptides with:

• Clinicians handling prescriptions
• 503A pharmacies compounding to USP standards
• Comprehensive lab testing through partner diagnostics
• A platform to manage these services

‍

Sources

July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee | FDA

‍